Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Efocipegtrutide

MARKETED

GLP-1/GIP/glucagon triple receptor agonist

2
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 2

Efocipegtrutide is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Efocipegtrutide MARKETED
hepatic-mash Decrease
Very low evidence

Efocipegtrutide (HM15211, Hanmi) is a long-acting GLP-1/GIP/glucagon triple co-agonist developed primarily for MASH/NASH rather than obesity. In a phase 1b/2a study it...

Abdelmalek MF et al. HM-TRIA-201: phase 2 study of HM15211 (efocipegtrutide) in biopsy-co... Source
Full findingEfocipegtrutide (HM15211, Hanmi) is a long-acting GLP-1/GIP/glucagon triple co-agonist developed primarily for MASH/NASH rather than obesity. In a phase 1b/2a study it significantly reduced liver fat and body weight in obese subjects with NAFLD; a phase 2 biopsy-confirmed NASH trial (HM-TRIA-201) followed.
PopulationPhase 1b/2a multicentre randomised placebo-controlled in obese subjects with NAFLD. Phase 2 HM-TRIA-201: adaptive randomised double-blind 52-week study, N=217 biopsy-confirmed NASH.
Fundingindustry - Hanmi (trial sponsor; inferred from registration trial)
Scope limitsno outcome data yet (design/protocol paper); small sample (N~217)
Comparatorsplacebo
Efocipegtrutide MARKETED
hepatic-mash Not directional
Very low evidence

Efocipegtrutide (HM15211; Hanmi, GLP-1/GIP/glucagon TRIPLE) is the closest published triple-agonist comparator to retatrutide for MASH, but its phase-2 histology trial...

Abdelmalek MF et al. Phase 2 52-week study of HM15211 in biopsy-confirmed NASH - design (... Source
Full findingEfocipegtrutide (HM15211; Hanmi, GLP-1/GIP/glucagon TRIPLE) is the closest published triple-agonist comparator to retatrutide for MASH, but its phase-2 histology trial (HM-TRIA-201) exists only as a PROTOCOL paper - no histologic outcome results published. The triple's MASH-resolution endpoint remains UNREAD in humans.
PopulationHM-TRIA-201 (protocol): planned N=217, biopsy NASH/MASH, adaptive RCT, 52 wk; primary = resolution without worsening fibrosis. Results pending.
Fundingindustry - Hanmi (trial sponsor; inferred from registration trial)
Scope limitsno outcome data yet (ongoing); small sample (N~217)
Comparatorsplacebo